Lexicon Pharmaceuticals Inc (LXRX)

14.52
0.93 6.02
NASDAQ : Health Care
Prev Close 15.45
Open 15.41
Day Low/High 14.41 / 15.64
52 Wk Low/High 7.65 / 16.98
Volume 787.33K
Avg Volume 630.20K
Exchange NASDAQ
Shares Outstanding 103.87M
Market Cap 1.62B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of LXRX August 19th Options Trading

First Week Of LXRX August 19th Options Trading

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the August 19th expiration.

7 Stocks Spiking on Big Volume

7 Stocks Spiking on Big Volume

Here's a technical look at how to trade seven stocks rising on unusual volume.

Lexicon To Report First Quarter 2016 Financial Results On May 3, 2016

Lexicon To Report First Quarter 2016 Financial Results On May 3, 2016

Conference Call and Webcast to Follow

Lexicon Pharmaceuticals (LXRX) Weak On High Volume Today

Lexicon Pharmaceuticals (LXRX) Weak On High Volume Today

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a weak on high relative volume candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BOBE, CETX, CTL, FNV, GRMN, INT, IVR, KE, LNN, LXRX, MCY, MEET, MNK, NVMI, SAVE, VIAV, WFM, Y, ZBH Downgrades: CHUY, FLO, LNCE, SYNL, WMB, WMC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Strong On High Volume: Lexicon Pharmaceuticals (LXRX)

Strong On High Volume: Lexicon Pharmaceuticals (LXRX)

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a strong on high relative volume candidate

Lexicon To Report Fourth Quarter And Year End 2015 Financial Results On March 1, 2016

Lexicon To Report Fourth Quarter And Year End 2015 Financial Results On March 1, 2016

Conference Call and Webcast to Follow

Lexicon Pharmaceuticals Enters Oversold Territory (LXRX)

Lexicon Pharmaceuticals Enters Oversold Territory (LXRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Short Interest Falls 10.8% For LXRX

Short Interest Falls 10.8% For LXRX

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 1,541,247 share decrease in total short interest for Lexicon Pharmaceuticals, Inc. , to 12,802,214, a decrease of 10.75% since 12/15/2015.

Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial

Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial

Results from Companion TELECAST Study Show Consistency with Clinical Benefit in Carcinoid Syndrome Observed in Pivotal TELESTAR Study, Support Planned Filings for Regulatory Approval

Stock To Watch: Lexicon Pharmaceuticals (LXRX) In Perilous Reversal

Stock To Watch: Lexicon Pharmaceuticals (LXRX) In Perilous Reversal

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a "perilous reversal" (up big yesterday but down big today) candidate